Abstrakt

Antibiotics are important for saving both human health and life. Antibiotics destroy all bacteria within their spectrum, because they do not distinguish between good and bad bacteria. Even if an antibiotic therapy lasts only a few days, it may cause diarrhoea and mycosis. Antibiotics destroy most bacterial species in the intestines. These changes may affect one’s whole life. Today it is a challenge for medicine to be able to manipulate the microbiome so as to restore normal relations between microorganisms. At present, when antibiotics are abused, probiotics are very often applied. However, as there are no recommendations, a lot of mistakes can be made when using them. Both drugs and dietary supplements can be classified as probiotics. Medicinal probiotics are subject to very strict registration requirements and their use is associated with a specific disease or ailment. Probiotic microorganisms must be classified according to their genus, species and strain. These preparations may contain one or more probiotic strains depending on its application. At present there are no established schemes or rules concerning the dosage of probiotic preparations. This issue arouses numerous controversies. It is assumed that the probiotic should be applied at a dose which proved to have a beneficial effect in tests conducted on humans. Patients usually make decisions on the choice and dosage of preparations themselves. Individualised probiotic therapy is the key to success. There is no universal preparation – a specific probiotic should be used in a particular clinical case.

Przypisy

• 1. Adams M.R., Marteau P.: On the safety of lactic acid bacteriafrom food. Int. J. Food Microbiol., 1995; 27: 263–264
  Google Scholar
• 2. Azad A.K., Sarker M., Li T., Yin J.: Probiotic species in the modulationof gut microbiota: An overview. Biomed. Res. Int., 2018;2018: 9478630
  Google Scholar
• 3. Bartnicka A., Szachta P., Gałęcka M.: Faecal microbiota transplant– prospects and safety. Pomeranian J. Life Sci., 2015; 61:282–286
  Google Scholar
• 4. Besselink M.G., van Santvoort H.C., Buskens E., BoermeesterM.A., van Goor H., Timmerman H.M., Nieuwenhuijs V.B., BollenT.L., van Ramshorst B., Witteman B.J., Rosman C., Ploeg R.J., BrinkM.A., Schaapherder A.F., Dejong C.H., et al.: Probiotic prophylaxisin predicted severe acute pancreatitis: a randomised, double-blind,placebo-controlled trial. Lancet, 2008; 371: 651–659
  Google Scholar
• 5. Binek M.: Mikrobiom człowieka – zdrowie i choroba. Post. Mikrobiol.,2012; 51: 27–36
  Google Scholar
• 6. Bischoff S.C., Escher J., Hébuterne X., Kłęk S., Krznaric Z., SchneiderS., Shamir R., Stardelova K., Wierdsma N., Wiskin A.E., ForbesA.: ESPEN practical guideline: Clinical nutrition in inflammatorybowel disease. Clin. Nutrition, 2020; 39: 632–653
  Google Scholar
• 7. Brown W.R.: Fecal microbiota transplantation in treatingClostridium difficile infection. J. Dig. Dis., 2014; 15: 405–408
  Google Scholar
• 8. Charteris W.P., Kelly P.M., Morelli L., Collins J.K.: Antibiotic susceptibilityof potentially probiotic Lactobacillus species. J. FoodProt., 1998; 61: 1636–1643
  Google Scholar
• 9. Cichy W., Gałęcka M., Szachta P.: Probiotyki jako alternatywnerozwiązanie i wsparcie terapii tradycyjnych. Zakażenia, 2010; 6: 2–8
  Google Scholar
• 10. Cremon C., Barbaro M.R., Ventura M., Barbara G.: Pre- and probioticoverview. Curr. Opin. Pharmacol., 2018; 43: 87–92
  Google Scholar
• 11. Curragh H.J., Collins M.A.: High levels of spontaneous drug resistancein Lactobacillus. J. Appl. Bacteriol., 1992; 73: 31–36
  Google Scholar
• 12. Dopuszczanie do obrotu suplementów diety. Najwyższa IzbaKontroli. https//www.nik.gov.pl/plik/id.13031,vp,15443.pdf.(18.12.2019)
  Google Scholar
• 13. Doron S., Snydman D.R.: Risk and safety of probiotics. Clin.Infect. Dis., 2015; 60, Suppl. 2: 129–134
  Google Scholar
• 14. Fenster K., Freeburg B., Hollard C., Wong C., RønhaveLaursenR., Ouwehand A.C.: The production and delivery of probiotics:A review of a practical approach. Microorganisms, 2019; 7: 83
  Google Scholar
• 15. Floch M.H., Walker W.A., Guandalini S., Hibberd P., Gorbach S.,Surawicz C., Sanders M.E., Garcia-Tsao G., Quigley E.M.M., IsolauriE., Fedorak R.N., Dieleman L.A.: Recommendations for probiotic use– 2008. J. Clin. Gastroenterol., 2008; 42, Suppl. 2: 104–108
  Google Scholar
• 16. Floch M.H., Walker W.A., Sanders M.E., Nieuwdorp M., KimA.S., Brenner D.A., Qamar A.A., Miloh T.A., Guarino A., Guslandi M.,Dieleman L.A., Ringel Y., Quigley E.M., Brandt L.J.: Recommendationsfor probiotic use – 2015 update: Proceedings and consensusopinion. J. Clin. Gastroenterol., 2015; 49, Suppl. 1: 69–73
  Google Scholar
• 17. Francino M.P.: Antibiotics and the human gut microbiome:dysbioses and accumulation of resistances. Front. Microbiol., 2016;6: 1543
  Google Scholar
• 18. Fric P.: Probiotics and prebiotics – renaissance of a therapeuticprinciple. Open Med., 2007; 2: 237–270
  Google Scholar
• 19. Gibson G.R., Rastall R.A., Roberfroid M.B.: Prebiotics. In: ColonicMicrobiota, Nutrition and Health. ed.: G.R. Gibson, M.B. Roberfroid.Springer Netherlands, Dordrecht 1999, 101–124
  Google Scholar
• 20. Główny Inspektorat Sanitarny – Gov.pl. https//www.gis.gov.pl/o-nas/aktualności/480-suplementy-kontrola-nik-i-uwagi-gis(20.01.2020)
  Google Scholar
• 21. Gomes D.O., de Morais M.B.: Gut microbiota and the use ofprobiotics in constipation in children and adolescents: systematicreview. Rev. Paul. Pediatr., 2019; 38: e2018123
  Google Scholar
• 22. Guarino A., Ashkenazi S., Gendrel D., Lo Vecchio A., ShamirR., Szajewska H., European Society for Pediatric Gastroenterology,Hepatology, and Nutrition, European Society for Pediatric InfectiousDiseases: European Society for Pediatric Gastroenterology,Hepatology, and Nutrition/European Society for Pediatric InfectiousDiseases evidence-based guidelines for the management ofacute gastroenteritis in children in Europe: update 2014. J. Pediatr.Gastroenterol. Nutr., 2014; 59: 132–152
  Google Scholar
• 23. Guidelines for the Evaluation of Probiotics in Food. Joint FAO/WHO Working Group Report on Draging Guidelines for the Evaluationof Probiotics in Food. London, Ontario, Canada, April 30 andMay 1, 2002 (20.11.2019)
  Google Scholar
• 24. Hamilton-Miller J.M., Shah S., Winkler J.T.: Public health issuesarising from microbiological and labelling quality of foods andsupplements containing probiotic microorganisms. Public HealthNutr., 1999; 2: 223–229
  Google Scholar
• 25. Hoa N.T., Baccigalupi L., Huxham A., Smertenko A., Van P.H.,Ammendola S., Ricca E., Cutting A.S.: Characterization of Bacillusspecies used for oral bacteriotherapy and bacterioprophylaxisof gastrointestinal disorders. Appl. Environ. Microbiol., 2000; 66:5241–5247
  Google Scholar
• 26. Holmes E., Li J.V., Athanasiou T., Ashrafian H., Nicholson J.K.:Understanding the role of gut microbiome-host metabolic signaldisruption in health and disease. Trends Microbiol., 2011; 19:349–359
  Google Scholar
• 27. Holzapfel W.H., Haberer P., Snel J., Schillinger U., Huis in’t VeldJ.H.: Overview of gut flora and probiotics. Int. J. Food Microbiol.,1998; 41: 85–101
  Google Scholar
• 28. Jach M., Łoś R., Maj M., Malm A.: Probiotyki – aspekty funkcjonalnei technologiczne. Post. Mikrobiol., 2013; 52: 161–170
  Google Scholar
• 29. Jernberg C., Löfmark S., Edlund C., Jansson J.K.: Long-termecological impacts of antibiotic administration on the human intestinalmicrobiota. ISME J, 2007; 1: 56–66
  Google Scholar
• 30. Kamińska E.: Skuteczność i bezpieczeństwo stosowania probiotykówna podstawie badań klinicznych przeprowadzonychu dzieci. Med. Wieku Rozwoj., 2012; 16: 240–251
  Google Scholar
• 31. Kaźmierska A.: Probiotyki – recepta na zdrowie? Kosmos, 2014;63: 455–472
  Google Scholar
• 32. Kim H.J., Vazquez Roque M.I., Camilleri M., Stephens D., BurtonD.D., Baxter K., Thomforde G., Zinsmeister A.R.: A randomizedcontrolled trial of a probiotic combination VSL#3 and placebo inirritable bowel syndrome with bloating. Neurogastroenterol. Motil.,2005; 17: 687–696
  Google Scholar
• 33. Kothari D., Patel S., Kim S.K.: Probiotic supplements mightnot be universally-effective and safe: A review. Biomed. Pharmacother.,2019; 111: 537–547
  Google Scholar
• 34. Krasnowska Y., Sikora T.: Suplementy diety a bezpieczeństwokonsumenta. Żywn. Nauka Technol. Jakość, 2011; 77: 5–23
  Google Scholar
• 35. Kubiszewska I., Januszewska M., Rybka J., Gackowska L.: Bakteriekwasu mlekowego i zdrowie: czy probiotyki są bezpieczne dlaczłowieka? Postępy Hig. Med. Dośw., 2014; 68: 1325–1334
  Google Scholar
• 36. Kuśmierska A., Fol M.: Właściwości immunomodulacyjnei terapeutyczne drobnoustrojów probiotycznych. Probl. Hig. Epidemiol,2014; 95: 529–540
  Google Scholar
• 37. La Fata G., Weber P., Mohajeri M.H.: Probiotics and the GutImmune System: Indirect Regulation. Probiotics Antimicrob. Proteins,2018; 10: 11–21
  Google Scholar
• 38. Lloyd-Price J., Abu-Ali G., Huttenhower C.: The healthy humanmicrobiome. Genome Med, 2016; 8: 51
  Google Scholar
• 39. Löfmark S., Jernberg C., Jansson J.K., Edlund C.: Clindamycininducedenrichment and long-term persistence of resistant Bacteroidesspp. and resistance genes. J. Antimicrob. Chemother.,2006; 58: 1160–1167
  Google Scholar
• 40. López-Moreno A., Aguilera M.: Probiotics dietary supplementationfor modulating endocrine and fertility microbiota dysbiosis.Nutrients, 2020; 12: 757
  Google Scholar
• 41. Lutyńska A., Augustynowicz E., Wiatrzyk A.: Problemy stosowaniasuplementów diety zawierających probiotyki. Probl. Hig.Epidemiol., 2012; 93: 493–498
  Google Scholar
• 42. Malla M.A., Dubey A., Kumar A., Yadav S., Hashem A., Abd AllahE.F.: Exploring the human microbiome: The potential future role ofnext–generation sequencing in disease diagnosis and treatment.Front. Immunol., 2019; 9: 2868
  Google Scholar
• 43. Manzanares W., Lemieux M., Langlois P.L., Wischmeyer P.E.:Probiotic and synbiotic therapy in critical illness: a systematicreview and meta-analysis. Crit. Care, 2016; 19: 262
  Google Scholar
• 44. Marcinkiewicz J., Ciszek M., Bobek M., Strus M., Heczko P.B.,Kurnyta M., Biedroń R., Chmielarczyk A.: Differential inflammatorymediator response in vitro from murine macrophages to lactobacilliand pathogenic intestinal bacteria. Int. J. Exp. Pathol.,2007; 88: 155–164
  Google Scholar
• 45. McDonald D., Ackermann G., Khailova L., Baird C., Heyland D.,Kozar R., Lemieux M., Derenski K., King J., Vis-Kampen C., KnightR., Wischmeyer P.E.: Extreme dysbiosis of the microbiome in criticalillness. mSphere, 2016; 1: e00199–00216
  Google Scholar
• 46. Miecznikow E.: O naturze ludzkiej. Zarys filozofii optymistycznej.Translated by F. Wermiński. Warszawa: Biblioteka Naukowa1907
  Google Scholar
• 47. Miele E., Pascarella F., Giannetti E., Quaglietta L., BaldassanoR.N., Staiano A.: Effect of a probiotic preparation (VSL#3) on inductionand maintenance of remission in children with ulcerativecolitis. Am. J. Gastroenterol., 2009; 104: 437–443
  Google Scholar
• 48. Mojka K.: Probiotyki, prebiotyki i synbiotyki – charakterystykai funkcje. Probl. Hig. Epidemiol., 2014; 95: 541–549
  Google Scholar
• 49. Monteagudo-Mera A., Rastall R.A., Gibson G.R., CharalampopoulosD., Chatzifragkou A.: Adhesion mechanisms mediated byprobiotics and prebiotics and their potential impact on humanhealth. Appl. Microbiol. Biotechnol., 2019; 103: 6463–6472
  Google Scholar
• 50. Mundula T., Ricci F., Barbetta B., Baccini M., Amedei A.: Effectof probiotics on oral candidiasis: A systematic review and metaanalysis.Nutrients, 2019; 11: 2449
  Google Scholar
• 51. Najwyższa Izba Kontroli. https://www.nik.gov.pl/aktualnosci/nik-o-dopuszczaniu-do-obrotu-suplementow-diety.html(27.4.2020)
  Google Scholar
• 52. Natural Health Products Ingredients Database. https://www.webprod.hc-sc.gc.ca/nhpid-bdipsn/dbImages/mono_probiotics_english.pdf. (15.01.2020)
  Google Scholar
• 53. Nowak A., Śliżewska K., Libudzisz Z: Probiotyki – historiai mechanizmy działania. Żywn. Nauka Technol. Jakość, 2010; 4: 5–19
  Google Scholar
• 54. Olszewska J., Jagusztyn-Krynicka E.K.: Human MicrobiomeProject – mikroflora jelit oraz jej wpływ na fizjologię i zdrowieczłowieka. Post. Mikrobiol., 2012; 51: 243–256
  Google Scholar
• 55. O’Toole P.W., Marchesi J.R., Hill C.: Next-generation probiotics:the spectrum from probiotics to live biotherapeutics. Nat. Microbiol.,2017; 2: 17057
  Google Scholar
• 56. Ouwehand A.C.: A review of dose-responses of probiotics inhuman studies. Benef. Microbes, 2017; 8: 143–151
  Google Scholar
• 57. Panasiuk A: Mikrobiota przewodu pokarmowego. WydawnictwoLekarskie PZWL, Warszawa 2019
  Google Scholar
• 58. Pattani R., Palda V.A., Hwang S.W., Shah P.S.: Probiotics forthe prevention of antibiotic-associated diarrhea and Clostridiumdifficile infection among hospitalized patients: Systematic reviewand meta-analysis. Open Med., 2013; 7: 56–67
  Google Scholar
• 59. Renter G.: Present and future of probiotics in Germany and inCentral Europe. Biosci. Microflora, 1997; 16: 43–51
  Google Scholar
• 60. Rudzki L., Szulc A.: Wpływ jelitowej flory bakteryjnej naośrodkowy układ nerwowy i jej potencjalne znaczenie w leczeniuzaburzeń psychicznych. Farmakoter. Psych. Neurol., 2013; 2: 69–77
  Google Scholar
• 61. Ruszkowski J., Szewczyk A., Witkowski J.M.: An overview of oralprebiotics, probiotics, synbiotics and post-biotic available on thePolish pharmacy market. Farm. Pol., 2018; 74: 114–122
  Google Scholar
• 62. Salminen S., von Wright A., Morelli L., Marteau P., Brassart D.,de Vos W.M., Fondén R., Saxelin M., Collins K., Mogensen G., BirkelandS.E., Mattila-Sandholm T.: Demonstration of safety of probiotics– a review. Int. J. Food Microbiol., 1998; 44: 93–106
  Google Scholar
• 63. Saxelin M., Lassig A., Karjalainen H., Tynkkynen S., SurakkaA., Vapaatalo H., Järvenpää S., Korpela R., Mutanen M., Hatakka K.:Persistence of probiotic strains in the gastrointestinal tract whenadministered as capsules, yoghurt, or cheese. Int. J. Food Microbiol.,2010; 144: 293–300
  Google Scholar
• 64. Schrezenmeir J., de Vrese M.: Probiotics, prebiotics, and synbiotics– approaching a definition. Am. J. Clin. Nutr., 2001; 73: 361–364
  Google Scholar
• 65. Suez J., Zmora N., Zilberman-Schapira G., Mor U., Dori-BachashM., Bashiardes S., Zur M., Regev-Lehavi D., Ben-Zeev BrikR., Federici S., Horn M., Cohen Y., Moor A.E., Zeevi D., Korem T.,et al.: Post-antibiotic gut mucosal microbiome reconstitution isimpaired by probiotics and improved by autologous FMT. Cell,2018; 174: 1406–1423
  Google Scholar
• 66. Summary of Product Characteristics (Charakterystyka ProduktuLeczniczego) Enterol. https://www.pub.rejestrymedyczne.csioz.gov.pl/Pobieranie.ashx?type=7890-c (15.11.2019)
  Google Scholar
• 67. Szachta P., Pazgrat M., Cichy W., Muszyński Z., Ignyś I.: Szczepyprobiotyczne –perspektywy i bezpieczeństwo. Gastroenterol.Pol., 2009; 16: 37–41
  Google Scholar
• 68. Szajewska H.: Praktyczne zastosowanie probiotyków. Gastroenterol.Klin., 2014; 6: 16–23
  Google Scholar
• 69. Szajewska H.: Probiotyki w Polsce – kiedy, jakie i dlaczego?Gastroenterol. Klin., 2010; 2: 1–9
  Google Scholar
• 70. Szajewska H.: Probiotyki w gastroenterologii – aktualny stanwiedzy. Gastroenterol. Klin., 2015; 7: 20–26
  Google Scholar
• 71. Szajewska H., Canani R.B., Guarino A., Hojsak I., Indrio F., KolacekS., Orel R., Shamir R., Vandenplas Y., van Goudoever J.B., WeizmanZ., ESPGHAN Working Group for ProbioticsPrebiotics: Probioticsfor the prevention of antibiotic-associated diarrhea in children.J. Pediatr. Gastroenterol. Nutr., 2016; 62: 495–506
  Google Scholar
• 72. Szajewska H., Guarino A., Hojsak I., Indrio F., Kolacek S., ShamirR., Vandenplas Y., Weizman Z., European Society for Pediatric Gastroenterology,Hepatology, and Nutrition: Use of probiotics formanagement of acute gastroenteritis: a position paper by the ESPGHANWorking Group for Probiotics and Prebiotics. J. Pediatr.Gastroenterol. Nutr., 2014; 58: 531–539
  Google Scholar
• 73. Szajewska H., Gyrczuk E., Horvath A.: Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants:a randomized, double-blind, placebo-controlled trial. J. Pediatr.,2013; 162: 257–262
  Google Scholar
• 74. Szajewska H., Kołodziej M., Gieruszczak-Białek D., Skórka A.,Ruszczyński M., Shamir R.: Systematic review with meta-analysis:Lactobacillus rhamnosus GG for treating acute gastroenteritis inchildren – a 2019 update. Aliment. Pharmacol. Ther., 2019; 49:1376–1384
  Google Scholar
• 75. Szymański H., Chmielarczyk A., Strus M., Pejcz J., Jawień M.,Kochan P., Heczko P.B.: Colonisation of the gastrointestinal tractby probiotic L. rhamnosus strains in acute diarrhoea in children.Dig. Liver Dis., 2006; 38, Suppl. 2: 274–276
  Google Scholar
• 76. The law on food safety and nutrition of 25 August 2006. Dz. U.2006r. Nr 171, poz.1225; (09.12.2019)
  Google Scholar
• 77. Tokarz-Deptuła B., Śliwa-Dominiak J., Adamiak M., Deptuła W.:Probiotyki a wybrane schorzenia u ludzi. Post. Mikrobiol., 2015;54: 133–140
  Google Scholar
• 78. Tompkins T.A., Mainville I., Arcand Y.: The impact of meals ona probiotic during transit through a model of the human uppergastrointestinal tract. Benef. Microbes, 2011; 2: 295–303
  Google Scholar
• 79. Tsai Y.L., Lin T.L., Chang C.J., Wu T.R., Lai W.F., Lu C.C., Lai H.C.:Probiotics, prebiotics and amelioration of diseases. J. Biomed. Sci.,2019; 26: 3
  Google Scholar
• 80. Wasilewska E., Złotkowska D., Pijagin M.E.: The role of intestinalmicroflora and probiotic bacteria in prophylactic and developmentof colorectal cancer. Postępy Hig. Med. Dośw., 2013;67: 837–847
  Google Scholar
• 81. Whorwell P.J., Altringer L., Morel J., Bond Y., Charbonneau D.,O’Mahony L., Kiely B., Shanahan F., Quigley E.M.: Efficacy of anencapsulated probiotic Bifidobacterium infantis 35624 in womenwith irritable bowel syndrome. Am. J. Gastroenterol., 2006; 101:1581–1590
  Google Scholar
• 82. World Gastroenterology Organisation Global Guidelines. Probioticsand prebiotics. https://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiotics-english (27.4.2020)
  Google Scholar
• 83. Yan F., Polk D.B.: Probiotics and immune health. Curr. Opin.Gastroenterol., 2011; 27: 496–501
  Google Scholar
• 84. Yoon M.Y., Yoon S.S.: Disruption of the gut ecosystem by antibiotics.Yonsei Med. J., 2018; 59: 4–12
  Google Scholar

Pełna treść artykułu